SCHEMBL21448005

SCHEMBL21448005

COc1cccc(Cl)c1N1CCN(C)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 6/20 0.56
DRD2 P14416 3/20 0.56
HTR1A P08908 4/20 0.43
HTR2A P28223 4/20 0.43
HTR2C P28335 4/20 0.43
DRD4 P21917 3/20 0.43
HTR2B P41595 3/20 0.43
HTR1D P28221 3/20 0.43
HTR1B P28222 1/20 0.43
HTR7 P34969 1/20 0.43
HTR6 P50406 1/20 0.43
HTR3E A5X5Y0 1/20 0.42
HTR3B O95264 1/20 0.42
HTR3A P46098 1/20 0.42
HTR3D Q70Z44 1/20 0.42
HTR3C Q8WXA8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TP53 P04637 1/20 0.42
DRD1 P21728 1/20 0.42
DRD5 P21918 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21448015 0.84 DRD2 (0.63) DRD3DRD2HTR1AHTR2AHTR2C
SCHEMBL31167417 0.82 ADRB1 (0.57) DRD3DRD2HTR1AHTR7HTR6
SCHEMBL31167421 0.82 ADRB1 (0.57) DRD3DRD2HTR1AHTR7HTR6
SCHEMBL6971975 0.81 DRD3 (0.57) DRD3DRD2HTR1AHTR2AHTR2C
SCHEMBL21447973 0.80 DRD3 (0.56) DRD3DRD2HTR1AHTR2AHTR2C
SCHEMBL9523246 0.80 DRD3 (0.56) DRD3DRD2HTR1AHTR2AHTR2C
SCHEMBL21599144 0.77 DRD2 (0.56) DRD3DRD2HTR1AHTR2AHTR2C
SCHEMBL20180553 0.77 DRD2 (0.56) DRD3DRD2HTR1AHTR2AHTR2C
SCHEMBL21448025 0.77 CHRM2 (0.43) DRD3DRD2HTR1ADRD4CYP2D6
SCHEMBL24310707 0.77 DRD2 (0.70) DRD3DRD2HTR1AHTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11345711-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones Impact Therapeutics (Shanghai), Inc (CN) 2022-05-31 US disclosed
WO-2021254389-A1 PYRAZOLO[3,4-D]PYRIMIDINE-3-KETONE DERIVATIVE AS WEE-1 INHIBITOR 微境生物医药科技(上海)有限公司 2021-12-23 WO disclosed
US-20200385394-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES Impact Therapeutics (Shanghai), Inc (CN) 2020-12-10 US disclosed
US-10703759-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones IMPACT THERAPEUTICS, INC (CN) 2020-07-07 US disclosed
US-20190308984-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES Impact Therapeutics (Shanghai), Inc (CN) 2019-10-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190308984-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES WEE1, WEE2, CCNE1 DRD3 4251/4885DRD2 4463/4885HTR1A 3666/4885
US-11345711-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones WEE1, WEE2, CCNE1 DRD3 4251/4885DRD2 4463/4885HTR1A 3666/4885
US-10703759-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones WEE1, WEE2, CCNE1 DRD3 4251/4885DRD2 4463/4885HTR1A 3666/4885
US-20200385394-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES WEE1, WEE2, CCNE1 DRD3 4251/4885DRD2 4463/4885HTR1A 3666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.